Corona Remedies IPO – Company Overview

Company Background

Incorporated in August 2004, Corona Remedies Limited is a fast-growing pharmaceutical company involved in the development, manufacturing, and marketing of products across multiple therapeutic areas, including women’s healthcare, cardiology, pain management, urology, and several multispecialty segments.

Diverse Product Portfolio

As of June 30, 2025, the company offers 71 brands across:

• Women’s healthcare

• Cardio-diabeto

• Pain management

• Urology

• Multispecialty pharmaceuticals (Vitamins/Minerals/Nutrition, Gastrointestinal, Respiratory)

This diversified portfolio allows the company to maintain a strong presence in high-demand therapeutic categories.

Wide Marketing & Distribution Network

Corona Remedies has established a strong pan-India presence, supported by:

• 2,671 medical representatives

• Coverage across 22 states

This extensive network enables effective engagement with healthcare professionals, hospitals, and clinics, enhancing its reach and positioning in the Indian Pharmaceutical Market (IPM).

Manufacturing Capabilities

• The company operates two manufacturing facilities in Gujarat, with a total installed capacity of 1,285.44 million units per annum.

• These facilities are backed by global quality certifications, ensuring adherence to stringent production standards for high-quality pharmaceutical formulations.

Corona Remedies IPO – Key Details

• IPO Dates: 8 – 10 December 2025

• Price Band: ₹1008 – ₹1062

• Lot Size: 14 shares

• Offer for Sale: ₹655.37 Cr

• Retail Quota: 35%

• GMP (Informational Only): ~25%

Allotment Link

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.